A practical reference on cyclic heptapeptide: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Synthetic cyclic heptapeptide |
| Molecular mass | Approximately 1024 g/mol | Depends on counter-ion content |
| Appearance | White to off-white powder | Commonly supplied as a lyophilised solid |
| Solubility | Freely soluble in water | Also dissolves in common aqueous buffers |
| Typical storage | -20 degrees Celsius, desiccated | Protect from light and repeated freeze-thaw |
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.
Pharmacologically, melanotan-2 behaves as a non-selective agonist across the melanocortin receptor family. Binding at MC1R on dermal melanocytes promotes eumelanin synthesis, which underlies the tanning response described in early human work. Activity at the centrally expressed MC4R receptor is associated with reported effects on appetite and erectile function. Because the peptide does not discriminate strongly among receptor subtypes, attributing any single observed effect to one receptor pathway is generally not possible without selective antagonists or receptor knockout models.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Melanotan-2, also written Melanotan II, is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, and the lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring. This structural change increases receptor affinity and metabolic stability relative to the native hormone. The compound was created in the 1980s as a research tool for studying pigmentation biology.
Melanocytes are the pigment-producing cells of the skin, and they carry melanocortin-1 receptors on their surface. When the receptor is activated, cyclic adenosine monophosphate rises inside the cell and raises the activity of enzymes such as tyrosinase, which increases melanin output. Melanotan-2 binds melanocortin-1 receptors in vitro and in animal models, and this binding is generally described as the basis for the tanning effect. Other receptors account for different effects: melanocortin-4 receptors contribute to appetite and erectile signalling, while melanocortin-3 and melanocortin-5 receptors contribute to energy balance and exocrine function.
Early published reports described melanotan-2 as a tanning agent without sun protection, which means darkening is not the same as protection against ultraviolet radiation. Later studies explored the peptide in erectile dysfunction, hemorrhagic shock, and some skin conditions. No regulator in the United States or Europe has approved it for clinical use. Many products labelled melanotan-2 are sold without approval and their identity and purity are unverified. Its long-term safety in humans remains an open question.
=== Mechanism of action === The mechanism of action of methocarbamol in humans has not been conclusively established. Its effect is thought to be localized to the central nervous system rather than a direct effect on skeletal muscles. It does not affect the motor end plate or the peripheral nerve fiber. The efficacy of the medication is likely related to its sedative effect. It has been shown in animal studies to act as a blocker of Nav1.4 voltage-gated sodium channels, but this may not be its only target.
Leonian Gyoku Rou (レオン星人ギョク・ロウ, Reon Seijin Gyoku Rō): Ban's leonine predecessor, from Planet Leon, who was meant to become Deka Red on Earth, but was badly injured while protecting Jasmine and Hoji from an Alienizer called Terry X, which seemingly forced Rou to retire. In reality, he was tasked by Numa-O to go underground and prepare an elite team called the Fire Squad (ファイヤースクワッド, Faiyā Sukuwaddo). In the present, after being forced out of hiding when Terry X resurfaces, Rou recruits Ban in recognition of his fiery passion and drive for crime-fighting. Gyoku Rou is voiced by Daisuke Namikawa (浪川 大輔, Namikawa Daisuke).
Liraglutide, sold under the brand name Victoza among others, is an anti-diabetic medication used to treat type 2 diabetes, and chronic obesity. It is a second-line therapy for diabetes following first-line therapy with metformin. Its effects on long-term health outcomes like heart disease and life expectancy are unclear. It is given by injection under the skin. Liraglutide is a glucagon-like peptide-1 receptor agonist (GLP-1 receptor agonist) also known as incretin mimetics. It works by increasing insulin release from the pancreas and decreases excessive glucagon release. Common side effects include low blood sugar, nausea, dizziness, abdominal pain, and pain at the site of injection. Gastrointestinal side-effects tend to be strongest at the beginning of treatment period and subside over time. Other serious side effects may include angioedema, pancreatitis, gallbladder disease, and kidney problems. Use in pregnancy and breastfeeding is of unclear safety. Liraglutide was approved for medical use in the European Union in 2009, and in the United States in 2010. It is available as a generic medication. In 2023, it was the 209th most commonly prescribed medication in the United States, with more than 2 million prescriptions.
== History == The chemical class of barbiturates are one of the oldest sedative-hypnotic agents known, dating back from the introduction of barbital in the early 20th century. In Hungary, hexobarbital (and other barbiturates) were regularly used as drugs by pregnant women attempting suicide. Hexobarbital was long thought to have potentially teratogenic and fetotoxic effects. The FDA has classified them as Pregnancy Category D or C. Some research however, indicate that ingestion of Hexobarbital might cause congenital abnormalities. During World War II, Herta Oberheuser was a Nazi physician and convicted war criminal, investigating the effects of hexobarbital. The experiments were mostly performed on woman prisoners in the Ravensbrück concentration camp.
== G == G3P – gall – gall-inducing insect – gamete – gametophyte – gastrula – gel electrophoresis – gene – genetic drift – gene duplication – gene pool – genetic code – genetic equilibrium – genetic fingerprint – genetic recombination – genetics – gene regulatory network – genetic carrier – gene therapy – genome – genome project – genomics – genotype – geologic time – George W. Beadle – glucose – glycolipid – glycolysis – glycome – glycomics – glycoprotein – glycoprotein – Gobind Khorana – Golgi apparatus – Gondwana – gradient – gravitational biology – gravitropism – Gregor Mendel – ground tissue – growth curve – Guthrie test
Sources: en.wikipedia.org
In November, Kennedy signed the act and issued an Executive Order tasking the Secretary of State to create, within the State Department, the "Agency for International Development" (or A.I.D.: subsequently re-branded as USAID), as the successor to both ICA and the Development Loan Fund. With these actions, the U.S. created a permanent agency working with administrative autonomy under the policy guidance of the State Department to implement, through resident field missions, a global program of both technical and financial development assistance for low-income countries. This structure has continued to date. Taking this momentum onto the world stage via an address to the UN General Assembly in September 1961, Kennedy called for a "United Nations Decade of Development". This initiative was endorsed by a General Assembly resolution in December, establishing the concepts of development and development assistance as global priorities.
=== Da === Valerie Daggett (BS 1993). American protein chemist at the University of Washington, known for molecular dynamics simulations of proteins and other biomolecules. John Call Dalton (1825–1889). American physiologist at the New York Metropolitan Board of Health, known for detailed and precise sketches of the brain. John W. Daly (1933–2008). American biochemist at the NIH, working primarily on alkaloids. Member Natl. Acad. Sci. USA. Marie Maynard Daly (1921–2003). American biochemist at the Albert Einstein College of Medicine, who studied the chemistry of histones, protein synthesis, the relationships between cholesterol and hypertension, and uptake of creatine by muscle cells. Keith Dalziel FRS (1921–1994). British biochemist at Oxford University, pioneer in analysis of the kinetics of two-substrate enzyme-catalysed reactions. Carl Peter Henrik Dam (1895–1976). Danish biochemist and physiologist at Copenhagen University who discovered vitamin K and its role in human physiology. Nobel Prize in Physiology or Medicine (1943). Marguerite Davis (1887–1967). American biochemist at the University of Wisconsin, co-discoverer of vitamins A and B Ronald W. Davis (b. 1941). American biochemist and geneticist at Stanford, known for developing new technologies in genomics. Member Natl. Acad. Sci. USA. Jean Dausset (1916–2009). French immunologist at INSERM who worked on the major histocompatibility complex. Nobel Prize in Physiology and Medicine (1980). Member Natl. Acad. Sci. USA. Member of the French Academy of Science Margaret Oakley Dayhoff (1925–1983).
=== From mechanical blood processing during surgery === In some surgical procedures (especially some heart operations) where substantial blood loss is expected, machinery is used for intraoperative blood salvage. A centrifuge process takes blood from the patient, washes the red blood cells with normal saline, and returns them to the patient's blood circulation. Hemolysis may occur if the centrifuge rotates too quickly (generally greater than 500 rpm)—essentially this is hemolysis occurring outside of the body. Increased hemolysis occurs with massive amounts of sudden blood loss, because the process of returning a patient's cells must be done at a correspondingly higher speed to prevent hypotension, pH imbalance, and a number of other hemodynamic and blood level factors. Modeling of fluid flows to predict the likelihood of red cell membrane rupture in response to stress is an active area of research.
=== Society === Little is revealed of the Combine's activities outside of Earth, but dialogue in Half-Life 2 states that they control worlds of various dimensions inhabited by a range of species. The Combine occupation of Earth is shown to be a brutal totalitarian police state. In City 17, an Eastern European city, Civil Protection units routinely conduct searches of apartment blocks, interrogating human citizens, and engaging in wanton police brutality. The military Overwatch forces of the Combine attack human resistance bases in an effort to further solidify their authority in the urban centers. Human citizens are clad in blue uniforms, living in designated apartment blocks and move around to different cities or locales in passenger trains by the Combine's will. Vortigaunts, enemy alien creatures from Half-Life, have also been enslaved, and are observed in various professions such as janitors. According to Half-Life 2: Raising the Bar, the Combine are draining Earth's oceans and resources to be used on other Combine worlds. The heart of the Combine's command over Earth in Half-Life 2 is the Citadel, a large tower constructed by them which reaches both tens of thousands of feet (several or several tens of kilometres) into the sky and deep underground. Located within City 17, the Citadel serves as the Combine's headquarters on Earth, housing Combine Advisors and the office of Earth's administrator, Dr. Wallace Breen. Breen, a puppet ruler, is frequently seen on large screens around the city on which he spreads propaganda and makes announcements.
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide and an analogue of alpha-melanocyte-stimulating hormone. The molecule is produced by chemical synthesis rather than extracted from a biological source.
It is shorter than the native hormone and carries a cyclic constraint that improves stability. These changes raise receptor potency and slow breakdown relative to the naturally occurring peptide.
Published accounts date its development to the 1980s, when researchers were generating analogues of melanocyte-stimulating hormone. That work aimed to produce more stable compounds for studying pigmentation biology.
It is a synthetic cyclic peptide designed as an analog of alpha-melanocyte-stimulating hormone. It acts on melanocortin receptors and is best known from research into pigmentation. It is not an approved pharmaceutical product.